CN107296799A - A kind of allicin tablet and preparation method thereof - Google Patents
A kind of allicin tablet and preparation method thereof Download PDFInfo
- Publication number
- CN107296799A CN107296799A CN201710543295.0A CN201710543295A CN107296799A CN 107296799 A CN107296799 A CN 107296799A CN 201710543295 A CN201710543295 A CN 201710543295A CN 107296799 A CN107296799 A CN 107296799A
- Authority
- CN
- China
- Prior art keywords
- allicin
- parts
- tablet
- preparation
- calcium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 title claims abstract description 113
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 title claims abstract description 113
- 235000010081 allicin Nutrition 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 32
- 238000000576 coating method Methods 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 27
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 27
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 27
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 27
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 25
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 25
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 25
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000007888 film coating Substances 0.000 claims description 21
- 238000009501 film coating Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- 235000020985 whole grains Nutrition 0.000 claims description 11
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 19
- 230000009286 beneficial effect Effects 0.000 abstract description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 6
- 239000011575 calcium Substances 0.000 abstract description 6
- 229910052791 calcium Inorganic materials 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 10
- 238000007689 inspection Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- -1 thio-allyl ether class compounds Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to field of health care products, in particular to a kind of allicin tablet and preparation method thereof.A kind of allicin tablet, is mainly made up of active ingredient and auxiliary material；The active ingredient includes：By weight, 82 90 parts of allicin, 0.5 1.5 parts of calcium phosphate, 30 35 parts of microcrystalline cellulose.The invention provides a kind of allicin tablet, calcium has the active effect of activation allicin, calcium phosphate and microcrystalline cellulose coordinated, increases the water solubility of allicin, is very beneficial for absorbing, obtained allicin tablet has effects that to be obviously improved body immunity.The preparation method for the allicin tablet that the present invention is provided, is progressively added to active ingredient and auxiliary material, and coating type allicin tablet is made, and this method technique is easy, and the active component influence on allicin is small.
Description
Technical field
The present invention relates to field of health care products, in particular to a kind of allicin tablet and preparation method thereof.
Background technology
Allicin is three thio-allyl ether class compounds, in the bulb for being naturally occurring in liliaceous plant garlic.To a variety of
Gram-positive and negative bacterium have antibacterial action, to bacillus (shigella dysenteriae, typhoid bacillus, Escherichia coli, Bordetella pertussis),
Fungi (Candida albicans, cryptococcus, aspergillus fumigatus), viral (cytomegalovirus), Amoeba, Trichomonas vaginalis, pinworm etc.
There is suppression killing action, strong especially is acted on to enteric bacteria such as Escherichia coli, shigella dysenteriaes.Clinical research discovery, this product pair
The concurrent cytomegalovirus infection of bone-marrow transplantation person has obvious preventive and therapeutic effect.Still there are reduction cholesterolemia, triglycerides and lipoprotein
And anti-platelet aggregation, antitumor action.Experiment shows that this product can prevent and treat liver fibrosis, is antioxidant.
Existing allicin product poorly water-soluble, stability is poor, and absorption difference is unfavorable for the marketization of product.
In view of this, it is special to propose the present invention.
The content of the invention
The first object of the present invention is to provide a kind of allicin tablet, active effect of the calcium with activation allicin, calcium phosphate
With microcrystalline cellulose coordinated, increase the water solubility of allicin, be very beneficial for absorbing, obtained allicin tablet, which has, significantly to be carried
Rise effect of body immunity.
The second object of the present invention is a kind of preparation method of described allicin tablet of offer, and this method technique is easy, right
The active component influence of allicin is small.
In order to realize the above-mentioned purpose of the present invention, spy uses following technical scheme：
A kind of allicin tablet, is mainly made up of active ingredient and auxiliary material；
The active ingredient includes：By weight, allicin 82-90 parts, 0.5-1.5 parts of calcium phosphate, microcrystalline cellulose 30-
35 parts.
The invention provides a kind of allicin tablet, calcium has the active effect of activation allicin, calcium phosphate and microcrystalline cellulose
Coordinated, increases the water solubility of allicin, is very beneficial for absorbing, and obtained allicin tablet, which has, is obviously improved body immunity
Effect.
Preferably, by weight, allicin 85-88 parts, 0.8-1.1 parts of calcium phosphate, 32-34 parts of cellulose.
Further, the auxiliary material includes：By weight, magnesium stearate 0.1-0.5 parts, enteric film coating powder 6.5-
3-7 parts of 7.5 parts, 90-95 parts of ethanol and water.
Present invention also offers the preparation method of above-mentioned allicin tablet, comprise the following steps：
(a) allicin, calcium phosphate and microcrystalline cellulose mixing, dry particl processed and whole grain；
(b) magnesium stearate, tabletting after mixing are added；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained, what the coating solution was obtained to tabletting
Tablet is coated, you can.
The preparation method for the allicin tablet that the present invention is provided, is progressively added to active ingredient and auxiliary material, and coating type allicin is made
Piece, this method technique is easy, and the active component influence on allicin is small.
Preferably, it is described to be mixed into step (a)：Using rotating speed as 10-15r/min mixing 20min.
Preferably, in step (a), during the dry particl processed, 14-16 eye mesh screens are crossed.
Preferably, it is described to be mixed into step (a)：Using rotating speed as 10-15r/min mixing 20min.
Preferably, in step (b), the weight of every of the tabletting is 0.6 ± 5%g.
Preferably, in step (c), the mass concentration of enteric film coating powder is 6.5%-7.5% in the coating solution.
Preferably, whole step is operated in 100,000 grades of clean areas.
Product after coating packed successively through bottle, outer packing, obtain commercially available prod after exfactory inspection.
Compared with prior art, beneficial effects of the present invention are：
(1) the invention provides a kind of allicin tablet, calcium has the active effect of activation allicin, calcium phosphate and microcrystalline cellulose
Plain coordinated, increases the water solubility of allicin, is very beneficial for absorbing, and obtained allicin tablet, which has, is obviously improved human immunity
Effect of power.
(2) preparation method for the allicin tablet that the present invention is provided, is progressively added to active ingredient and auxiliary material, and coating type garlic is made
Plain piece, this method technique is easy, and the active component influence on allicin is small.
Embodiment
One aspect of the present invention is related to a kind of allicin tablet, is mainly made up of active ingredient and auxiliary material；
The active ingredient includes：By weight, allicin 82-90 parts, 0.5-1.5 parts of calcium phosphate, microcrystalline cellulose 30-
35 parts.
The invention provides a kind of allicin tablet, calcium has the active effect of activation allicin, calcium phosphate and microcrystalline cellulose
Coordinated, increases the water solubility of allicin, is very beneficial for absorbing, and obtained allicin tablet, which has, is obviously improved body immunity
Effect.
In order to further enhance the collaboration enhancing effect between each raw material, it is preferable that by weight, 85-88 parts of allicin,
0.8-1.1 parts of calcium phosphate, 32-34 parts of cellulose.
Water-soluble influence of the active ingredient on allicin is very big, but auxiliary material also has large effect to obtained product.
Allicin product forms of the prior art are a variety of, still, and the effect that is absorbed by the body need further lifting.Invention
People is had been surprisingly found that, allicin is carried out into casing parcel, compared to gel, granule etc., the assimilation effect of allicin is effectively increased.
Further, the auxiliary material includes：By weight, magnesium stearate 0.1-0.5 parts, enteric film coating powder 6.5-
3-7 parts of 7.5 parts, 90-95 parts of ethanol and water.
Another aspect of the present invention further relates to the preparation method of above-mentioned allicin tablet, comprises the following steps：
(a) allicin, calcium phosphate and microcrystalline cellulose mixing, dry particl processed and whole grain；
(b) magnesium stearate, tabletting after mixing are added；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained, what the coating solution was obtained to tabletting
Tablet is coated, you can.
The preparation method for the allicin tablet that the present invention is provided, is progressively added to active ingredient and auxiliary material, and coating type allicin is made
Piece, this method technique is easy, and the active component influence on allicin is small.
Preferably, it is described to be mixed into step (a)：Using rotating speed as 10-15r/min mixing 20min.Such as mixing to be
Using rotating speed as 10r/min mixing 20min, using rotating speed as 12r/min mixing 20min, using rotating speed as 15r/min mixing 20min etc.
Deng.
With mixed on low speed for a period of time, magnesium stearate can be preferably well mixed with particle, easy to operate.By allicin, phosphorus
Dry particl is first made in sour calcium and microcrystalline cellulose mixing, beneficial to the distribution uniformity of these three compositions, also, is carried for follow-up coating
For good condition.
Obtained granular size is appropriate, beneficial to follow-up tabletting.Preferably, in step (a), during the dry particl processed, 14- is crossed
16 eye mesh screens.After whole grain, 14-16 eye mesh screens are also crossed.
Preferably, it is described to be mixed into step (b)：Using rotating speed as 10-15r/min mixing 20min.With mixed on low speed one
The section time, magnesium stearate can be preferably well mixed with particle, easy to operate, and on particle active principle without influence.
Preferably, in step (b), the weight of every of the tabletting is 0.6 ± 5%g.
The size of the tablet is suitable, instant edible.
Preferably, in step (c), the mass concentration of enteric film coating powder is 6.5%-7.5% in the coating solution.Should
The coating solution of concentration is beneficial to be coated tablet homogeneity, also, the thickness of the coating solution coating of the concentration is appropriate, beneficial to people
Body absorbs.
Preferably, whole step is operated in 100,000 grades of clean areas.
Allicin tablet is prepared under sterile conditions, it is therefore prevented that destruction of the high temperature process to allicin, be effectively retained each
The activity of active ingredient.
Product after coating packed successively through bottle, outer packing, obtain commercially available prod after exfactory inspection.
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the present invention.It is unreceipted specific in embodiment
Condition person, the condition advised according to normal condition or manufacturer is carried out.Agents useful for same or the unreceipted production firm person of instrument, be
The conventional products that can be obtained by commercially available purchase.
Embodiment 1
A kind of allicin tablet, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：82 parts of allicin, 0.5 part of calcium phosphate, 30 parts of microcrystalline cellulose；
Auxiliary material：3 parts of 0.1 part of magnesium stearate, 6.5 parts of enteric film coating powder, 90 parts of ethanol and water；
Technological process：
(a) allicin, calcium phosphate and microcrystalline cellulose are using rotating speed as 10r/min mixing 20min, and extruding crushing is made dry
Grain, crosses 14 eye mesh screens, and whole grain crosses 14 eye mesh screens；
(b) magnesium stearate is added, using rotating speed as 10r/min mixing 20min, tabletting, the weight of every is 0.6 ± 5%g；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained；
Tablet that coating solution is obtained to tabletting is coated, and is then packed through bottle, outer packing, exfactory inspection obtain allicin tablet production
Product.
Embodiment 2
A kind of allicin tablet, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：85 parts of allicin, 0.8 part of calcium phosphate, 32 parts of microcrystalline cellulose；
Auxiliary material：5 parts of 0.2 part of magnesium stearate, 7 parts of enteric film coating powder, 92 parts of ethanol and water；
Technological process：
(a) allicin, calcium phosphate and microcrystalline cellulose are using rotating speed as 15r/min mixing 20min, and extruding crushing is made dry
Grain, crosses 16 eye mesh screens, and whole grain crosses 16 eye mesh screens；
(b) magnesium stearate is added, using rotating speed as 15r/min mixing 20min, tabletting, the weight of every is 0.6 ± 5%g；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained；
Tablet that coating solution is obtained to tabletting is coated, and is then packed through bottle, outer packing, exfactory inspection obtain allicin tablet production
Product.
Embodiment 3
A kind of allicin tablet, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：86 parts of allicin, 0.9 part of calcium phosphate, 32.9 parts of microcrystalline cellulose；
Auxiliary material：5.06 parts of 0.2 part of magnesium stearate, 7.2 parts of enteric film coating powder, 90.6 parts of ethanol and water；
Technological process：
(a) allicin, calcium phosphate and microcrystalline cellulose are using rotating speed as 15r/min mixing 20min, and extruding crushing is made dry
Grain, crosses 14 eye mesh screens, and whole grain crosses 14 eye mesh screens；
(b) magnesium stearate is added, using rotating speed as 15r/min mixing 20min, tabletting, the weight of every is 0.6 ± 5%g；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained；
Tablet that coating solution is obtained to tabletting is coated, and is then packed through bottle, outer packing, exfactory inspection obtain allicin tablet production
Product.
Embodiment 4
A kind of allicin tablet, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：88 parts of allicin, 1.1 parts of calcium phosphate, 34 parts of microcrystalline cellulose；
Auxiliary material：5 parts of 0.3 part of magnesium stearate, 7 parts of enteric film coating powder, 92 parts of ethanol and water；
Technological process：
(a) allicin, calcium phosphate and microcrystalline cellulose are using rotating speed as 15r/min mixing 20min, and extruding crushing is made dry
Grain, crosses 14 eye mesh screens, and whole grain crosses 14 eye mesh screens；
(b) magnesium stearate is added, using rotating speed as 15r/min mixing 20min, tabletting, the weight of every is 0.6 ± 5%g；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained；
Tablet that coating solution is obtained to tabletting is coated, and is then packed through bottle, outer packing, exfactory inspection obtain allicin tablet production
Product.
Embodiment 5
A kind of allicin tablet, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：90 parts of allicin, 1.5 parts of calcium phosphate, 35 parts of microcrystalline cellulose；
Auxiliary material：7 parts of 0.5 part of magnesium stearate, 7.5 parts of enteric film coating powder, alcohol 95 part and water；
Technological process：
(a) allicin, calcium phosphate and microcrystalline cellulose are using rotating speed as 12r/min mixing 20min, and extruding crushing is made dry
Grain, crosses 15 eye mesh screens, and whole grain crosses 15 eye mesh screens；
(b) magnesium stearate is added, using rotating speed as 12r/min mixing 20min, tabletting, the weight of every is 0.6 ± 5%g；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained；
Tablet that coating solution is obtained to tabletting is coated, and is then packed through bottle, outer packing, exfactory inspection obtain allicin tablet production
Product.
Comparative example 1
A kind of allicin tablet, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：86 parts of allicin；
Auxiliary material：5.06 parts of 0.2 part of magnesium stearate, 7.2 parts of enteric film coating powder, 90.6 parts of ethanol and water；
Technological process：
(a) dry particl is made in allicin extruding crushing, crosses 14 eye mesh screens, and whole grain crosses 14 eye mesh screens；
(b) magnesium stearate is added, using rotating speed as 15r/min mixing 20min, tabletting, the weight of every is 0.6 ± 5%g；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution is obtained；
Tablet that coating solution is obtained to tabletting is coated, and is then packed through bottle, outer packing, exfactory inspection obtain allicin tablet production
Product.
Comparative example 2
A kind of allicin granule, following operate is carried out in 100,000 grades of clean areas：
By weight, following raw material is taken：
Active ingredient：86 parts of allicin, 0.9 part of calcium phosphate, 32.9 parts of microcrystalline cellulose；
Technological process：
Allicin, calcium phosphate and microcrystalline cellulose are using rotating speed as 15r/min mixing 20min, and dry particl, mistake is made in extruding crushing
14 eye mesh screens, whole grain crosses 14 eye mesh screens；
Pack, outer packing, exfactory inspection obtain allicin product.
Experimental example 1
It will remove and be dissolved in water after being coated made from embodiment 1-5, comparative example 1 is dissolved in water after removing coating, comparative example 2
Obtained particle is dissolved in water, and each group dissolving homogeneity is investigated after dissolving completely, 24h is placed, sees whether be layered, and hear allicin
Taste.As a result it is as shown in table 1.
The performance detection of table 1
Found when being dissolved in water, tablet made from 1-5 of the embodiment of the present invention is removed after coat, good water solubility, obtained liquid
Body is emulsus, not stratified, and allicin is not easy to be oxidized；And as shown in comparative example 1, the poorly water-soluble of allicin itself.
Experimental example 2
Allicin product in embodiment 1-5 and comparative example 2 is edible through volunteer, it is edible after detect that allicin contains in its blood
Amount.As a result find, eat the allicin content in 1-5 of the embodiment of the present invention apparently higher than the allicin content of edible comparative example 2.Explanation
Allicin product good absorbing effect produced by the present invention.
Experimental example 3
Eating effect detection is carried out to allicin tablet made from embodiment 1-5, while being produced with allicin made from comparative example 1 and 2
Product are as a control group.Mainly for hypoimmunity crowd (totally 350 people, is divided into 7 groups, the edible not be the same as Example of correspondence and
The allicin tea product that control group is provided, eating method is：Twice daily, each two panels.It it is respectively 1 month, 3 months in edible time
Investigation was tracked with 6 months.
Investigation is found, is drunk after the allicin tablet that the present invention is provided, all to reach following effect per capita：
At 1 month, sense of fatigue mitigates；
At 3 months, no longer often feel fatigue；
At 6 months, the whole body is easily strong, no longer often catches a cold.
Allicin tablet difference on effect is not obvious made from be the same as Example.
But, the crowd of edible comparative example 1 effect that banishes the feeling of languor is significantly worse than 1-5 of embodiment of the present invention product, food
The effect that banished the feeling of languor with the crowd of comparative example 2 is worse than 1-5 of embodiment of the present invention product.
It can be seen that, the allicin tablet that the present invention is provided has obvious dispelling fatigue, the effect of strengthen immunity.
Although illustrate and describing the present invention with specific embodiment, but it will be appreciated that without departing substantially from the present invention's
Many other changes and modification can be made in the case of spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (10)
1. a kind of allicin tablet, it is characterised in that be mainly made up of active ingredient and auxiliary material；
The active ingredient includes：By weight, allicin 82-90 parts, 0.5-1.5 parts of calcium phosphate, microcrystalline cellulose 30-35
Part.
2. allicin tablet according to claim 1, it is characterised in that by weight, 85-88 parts of allicin, calcium phosphate 0.8-
1.1 parts, 32-34 parts of cellulose.
3. allicin tablet according to claim 1 or 2, it is characterised in that the auxiliary material includes：By weight, stearic acid
3-7 parts of 0.1-0.5 parts of magnesium, 6.5-7.5 parts of enteric film coating powder, 90-95 parts of ethanol and water.
4. the preparation method of the allicin tablet described in claim any one of 1-3, it is characterised in that comprise the following steps：
(a) allicin, calcium phosphate and microcrystalline cellulose mixing, dry particl processed and whole grain；
(b) magnesium stearate, tabletting after mixing are added；
(c) after mixing enteric film coating powder, second alcohol and water, coating solution, the tablet that the coating solution is obtained to tabletting are obtained
It is coated, you can.
5. the preparation method of allicin tablet according to claim 4, it is characterised in that in step (a), described to be mixed into：With
Rotating speed is 10-15r/min mixing 20min.
6. the preparation method of allicin tablet according to claim 4, it is characterised in that in step (a), the dry particl processed
When, cross 14-16 eye mesh screens.
7. the preparation method of allicin tablet according to claim 4, it is characterised in that in step (b), described to be mixed into：With
Rotating speed is 10-15r/min mixing 20min.
8. the preparation method of allicin tablet according to claim 4, it is characterised in that in step (b), every of the tabletting
Weight be 0.6 ± 5%g.
9. intestines in the preparation method of allicin tablet according to claim 4, it is characterised in that in step (c), the coating solution
The mass concentration of molten film coating powder is 6.5%-7.5%.
10. the preparation method of the allicin tablet according to claim any one of 4-9, it is characterised in that whole step is 100,000
Level clean area operation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710543295.0A CN107296799A (en) | 2017-07-05 | 2017-07-05 | A kind of allicin tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710543295.0A CN107296799A (en) | 2017-07-05 | 2017-07-05 | A kind of allicin tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107296799A true CN107296799A (en) | 2017-10-27 |
Family
ID=60136220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710543295.0A Pending CN107296799A (en) | 2017-07-05 | 2017-07-05 | A kind of allicin tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107296799A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476867A (en) * | 2002-08-21 | 2004-02-25 | 上海方远科技发展有限公司 | Freeze-dried garlic powder preparation and its preparation method |
| CN101134079A (en) * | 2006-08-28 | 2008-03-05 | 天津威欧斯生物科技发展有限公司 | Slimming agent made by garlic |
| CN101342148A (en) * | 2008-07-03 | 2009-01-14 | 姚英 | Quick-effective antimicrobial, anti-inflammation, antiviral hyperconcentrated natural allicin tablet and preparation method thereof |
| CN102380020A (en) * | 2011-11-10 | 2012-03-21 | 新疆维吾尔自治区中药民族药研究所 | Garlic enteric-coated tablets and production method thereof |
| CN104771418A (en) * | 2015-03-19 | 2015-07-15 | 苏州谷力生物科技有限公司 | Foot-bath effervescent tablet and preparation method thereof |
| CN106307547A (en) * | 2016-08-24 | 2017-01-11 | 徐金蝶 | Lipid-lowering health piece with garlicin and preparing method thereof |
-
2017
- 2017-07-05 CN CN201710543295.0A patent/CN107296799A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476867A (en) * | 2002-08-21 | 2004-02-25 | 上海方远科技发展有限公司 | Freeze-dried garlic powder preparation and its preparation method |
| CN101134079A (en) * | 2006-08-28 | 2008-03-05 | 天津威欧斯生物科技发展有限公司 | Slimming agent made by garlic |
| CN101342148A (en) * | 2008-07-03 | 2009-01-14 | 姚英 | Quick-effective antimicrobial, anti-inflammation, antiviral hyperconcentrated natural allicin tablet and preparation method thereof |
| CN102380020A (en) * | 2011-11-10 | 2012-03-21 | 新疆维吾尔自治区中药民族药研究所 | Garlic enteric-coated tablets and production method thereof |
| CN104771418A (en) * | 2015-03-19 | 2015-07-15 | 苏州谷力生物科技有限公司 | Foot-bath effervescent tablet and preparation method thereof |
| CN106307547A (en) * | 2016-08-24 | 2017-01-11 | 徐金蝶 | Lipid-lowering health piece with garlicin and preparing method thereof |
Non-Patent Citations (3)
| Title |
|---|
| HTTP://BLOG.SINA.COM.CN/S/BLOG_86B302890102XJWQ.HTML: "罗麦蒜素片的功效和使用方法", 《和合的博客》 * |
| HTTPS://WENKU.BAIDU.COM/VIEW/2FE07DD233D4B14E8524686C.HTML: "大蒜素制剂的制备及质量研究", 《百度文库》 * |
| 彭继千: "大蒜活性蛋白提取、分离及制剂工艺的研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010095454A (en) | Antibacterial composition | |
| CN101524375B (en) | Wet-process wall breaking method of lucidum spore powder | |
| KR101539508B1 (en) | Functional salt and the manufacture method | |
| CN105580883A (en) | Biological fresh-keeping agent effervescent granules or tablets | |
| CN110881528A (en) | Production technology of highland barley bean pollen rich in gamma-aminobutyric acid and ferulic acid | |
| Gallo et al. | Applications of chitosan as a functional food | |
| WO1998025481A1 (en) | Fermented garlic composition | |
| Hanif et al. | Formulation of active packaging system using Artemisia scoparia for enhancing shelf life of fresh fruits | |
| Thipe et al. | Green nanotechnology: nanoformulations against toxigenic fungi to limit mycotoxin production | |
| CN108041578A (en) | Barley young leaf green juice powder and its processing technology | |
| CN104585244A (en) | Method for preparing radix fici simplicissimae extract, radix fici simplicissimae extract and application of extract | |
| CN107296799A (en) | A kind of allicin tablet and preparation method thereof | |
| CN108221473A (en) | A kind of paper pulp and preparation method thereof | |
| CN107890001A (en) | A kind of potpourri plant gas phase bacteriostatic agent | |
| CN105852051A (en) | Long-shelf-life fermented soybean and preparation method thereof | |
| CN109430687A (en) | A kind of composition can be used as aflatoxin scavenger | |
| US11389500B2 (en) | Liquid invisible mask with broad-spectrum bacteriostasis and preparation method and using method thereof | |
| US20100273737A1 (en) | Supplementary food composition for reducing body odor | |
| JP2829561B2 (en) | Ultraviolet irradiation culture Basidiomycete mycelium | |
| CN107375065A (en) | It is a kind of that there is the composition and preparation method for safeguarding and recovering the effect of skin Tiny ecosystem | |
| CN105496982A (en) | Chitosan tablets and preparation method thereof | |
| KR20110134123A (en) | Method for production of fermented composition using guava leaf powder | |
| CN117158493B (en) | Pu' er cordyceps white tea and preparation method thereof, and shaking box | |
| CN104000200A (en) | Multifunctional roxburgh rose fruits and preparing method thereof | |
| CN109452426A (en) | A kind of highly concentrated tea-drinking of quintessence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171027 |